Sensei Biotherapeutics, Inc.

NasdaqGM:SNSE 株式レポート

時価総額:US$12.3m

Sensei Biotherapeutics マネジメント

マネジメント 基準チェック /24

Sensei Biotherapeutics' CEO is John Celebi, appointed in Feb 2018, has a tenure of 6.75 years. total yearly compensation is $1.01M, comprised of 52.6% salary and 47.4% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $30.63K. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.

主要情報

John Celebi

最高経営責任者

US$1.0m

報酬総額

CEO給与比率52.6%
CEO在任期間6.8yrs
CEOの所有権0.2%
経営陣の平均在職期間1.9yrs
取締役会の平均在任期間3.8yrs

経営陣の近況

Recent updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Aug 14
We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Aug 09

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Apr 18
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Nov 16
Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

CEO報酬分析

Sensei Biotherapeutics の収益と比較して、John Celebi の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$30m

Mar 31 2024n/an/a

-US$32m

Dec 31 2023US$1mUS$532k

-US$34m

Sep 30 2023n/an/a

-US$39m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$46m

Dec 31 2022US$2mUS$513k

-US$49m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$42m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$7mUS$487k

-US$37m

Sep 30 2021n/an/a

-US$33m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$2mUS$395k

-US$20m

報酬と市場: John's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD655.65K).

報酬と収益: John's compensation has been consistent with company performance over the past year.


CEO(最高経営責任者

John Celebi (52 yo)

6.8yrs

在職期間

US$1,012,289

報酬

Mr. John K. Celebi, MBA serves as President, Chief Executive Officer and Director of Alvaxa Biosciences, Incorporated since February 2018. Mr. Celebi serves as President and Chief Executive Officer of Sens...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
John Celebi
President6.8yrsUS$1.01m0.25%
$ 30.6k
Edward Van der Horst
Chief Scientific Officer1.9yrsUS$739.08k0.14%
$ 17.4k
Josiah Craver
Senior VP of Financeless than a yearデータなしデータなし
Lora Pike
Vice President of Investor Relations & Communicationsno dataデータなしデータなし
Christopher Gerry
Senior VP2.3yrsデータなしデータなし
Stephanie Krebs
Chief Business Officerless than a yearデータなしデータなし
Aaron Weitzman
Chief Medical Officerno dataデータなしデータなし

1.9yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: SNSE's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


取締役

名称ポジション在職期間報酬所有権
John Celebi
President6.8yrsUS$1.01m0.25%
$ 30.6k
Thomas Ricks
Independent Director8.9yrsUS$75.56k1.35%
$ 166.3k
William Ringo
Independent Chairman2.7yrsUS$101.57k0.063%
$ 7.8k
Robert Holmen
Independent Director7.8yrsUS$73.39k0.084%
$ 10.4k
Richard Ulevitch
Member of Immuno-Oncology Advisory Board3.5yrsデータなしデータなし
Deneen Vojta
Independent Director3.8yrsUS$69.32k0.018%
$ 2.2k
James Peyer
Independent Director4.8yrsUS$68.43kデータなし
Alain Algazi
Member of Immuno-Oncology Advisory Boardno dataデータなしデータなし
Maura Gillison
Member of Immuno-Oncology Advisory Board3.5yrsデータなしデータなし
Kristian Humer
Independent Director3.3yrsUS$62.24k0.018%
$ 2.2k
Sara Pai
Member of Immuno-Oncology Advisory Boardno dataデータなしデータなし
Robert Schreiber
Member of Immuno-Oncology Advisory Boardno dataデータなしデータなし

3.8yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: SNSE's board of directors are considered experienced (3.8 years average tenure).